Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement
Jamie E. Flerlage
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
Search for more papers by this authorKara M. Kelly
Roswell Park Cancer Institute, University of Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York
Search for more papers by this authorAuke Beishuizen
Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands
Search for more papers by this authorSteve Cho
Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Search for more papers by this authorPedro A. De Alarcon
University of Illinois College of Medicine, Peoria, Illinois
Search for more papers by this authorUte Dieckmann
Klinik für Strahlenheilkunde, Universitätsklinik Freiburg, Freiburg, Germany
Search for more papers by this authorRichard A. Drachtman
Division of Pediatric Hematology Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Search for more papers by this authorBradford S. Hoppe
Department of Radiation Oncology, University of Florida, Gainesville, Florida
Search for more papers by this authorScott C. Howard
University of Memphis School of Health Studies, Memphis, Tennessee
Search for more papers by this authorSue C. Kaste
Department of Diagnostic Imaging, University of Tennessee Health Sciences Center, Memphis, Tennessee
Search for more papers by this authorRegine Kluge
Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany
Search for more papers by this authorLars Kurch
Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany
Search for more papers by this authorJudith Landman-Parker
Department of Paediatric Haematology & Oncology, Hôpital Trousseau AP-HP & Université Pierre et Marie Curie, Paris, France
Search for more papers by this authorJocelyn Lewis
Division of Pediatric Hematology Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Search for more papers by this authorMichael P. Link
Division of Pediatric Hematology-Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California
Search for more papers by this authorKathleen McCarten
Rhode Island Hospital/Warren Alpert Medical School at Brown University, Providence, Rhode Island
Search for more papers by this authorAngela Punnett
Division of Haematology/Oncology, Department of Paediatrics, SickKids Hospital and University of Toronto, Toronto, Canada
Search for more papers by this authorDietrich Stoevesandt
University Clinic Halle (Saale), Halle, Germany
Search for more papers by this authorStephan D. Voss
Department of Radiology, Boston Children's Hospital Dana-Farber Cancer Institute, Boston, Massachusetts
Search for more papers by this authorWilliam Hamish Wallace
Royal Hospital for Sick Children, Edinburgh, Scotland, UK
Search for more papers by this authorChristine Mauz-Körholz
Department of Pädiatrische Hämatologie und Onkologie, Zentrum für Kinderheilkunde der Justus-Liebig-Universität Gießen, Gießen, Germany
Medical Faculty, Martin-Luther-University of Halle-Wittenberg, Halle, Germany
Christine Mauz-Korholz and Monika L. Metzger contributed equally to the writing of the manuscript.
Search for more papers by this authorCorresponding Author
Monika L. Metzger
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
Christine Mauz-Korholz and Monika L. Metzger contributed equally to the writing of the manuscript.
Correspondence
Monika L. Metzger, Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105.
Email: [email protected]
Search for more papers by this authorJamie E. Flerlage
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
Search for more papers by this authorKara M. Kelly
Roswell Park Cancer Institute, University of Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York
Search for more papers by this authorAuke Beishuizen
Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands
Search for more papers by this authorSteve Cho
Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Search for more papers by this authorPedro A. De Alarcon
University of Illinois College of Medicine, Peoria, Illinois
Search for more papers by this authorUte Dieckmann
Klinik für Strahlenheilkunde, Universitätsklinik Freiburg, Freiburg, Germany
Search for more papers by this authorRichard A. Drachtman
Division of Pediatric Hematology Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Search for more papers by this authorBradford S. Hoppe
Department of Radiation Oncology, University of Florida, Gainesville, Florida
Search for more papers by this authorScott C. Howard
University of Memphis School of Health Studies, Memphis, Tennessee
Search for more papers by this authorSue C. Kaste
Department of Diagnostic Imaging, University of Tennessee Health Sciences Center, Memphis, Tennessee
Search for more papers by this authorRegine Kluge
Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany
Search for more papers by this authorLars Kurch
Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany
Search for more papers by this authorJudith Landman-Parker
Department of Paediatric Haematology & Oncology, Hôpital Trousseau AP-HP & Université Pierre et Marie Curie, Paris, France
Search for more papers by this authorJocelyn Lewis
Division of Pediatric Hematology Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Search for more papers by this authorMichael P. Link
Division of Pediatric Hematology-Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California
Search for more papers by this authorKathleen McCarten
Rhode Island Hospital/Warren Alpert Medical School at Brown University, Providence, Rhode Island
Search for more papers by this authorAngela Punnett
Division of Haematology/Oncology, Department of Paediatrics, SickKids Hospital and University of Toronto, Toronto, Canada
Search for more papers by this authorDietrich Stoevesandt
University Clinic Halle (Saale), Halle, Germany
Search for more papers by this authorStephan D. Voss
Department of Radiology, Boston Children's Hospital Dana-Farber Cancer Institute, Boston, Massachusetts
Search for more papers by this authorWilliam Hamish Wallace
Royal Hospital for Sick Children, Edinburgh, Scotland, UK
Search for more papers by this authorChristine Mauz-Körholz
Department of Pädiatrische Hämatologie und Onkologie, Zentrum für Kinderheilkunde der Justus-Liebig-Universität Gießen, Gießen, Germany
Medical Faculty, Martin-Luther-University of Halle-Wittenberg, Halle, Germany
Christine Mauz-Korholz and Monika L. Metzger contributed equally to the writing of the manuscript.
Search for more papers by this authorCorresponding Author
Monika L. Metzger
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
Christine Mauz-Korholz and Monika L. Metzger contributed equally to the writing of the manuscript.
Correspondence
Monika L. Metzger, Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105.
Email: [email protected]
Search for more papers by this authorAbstract
International harmonization of staging evaluation and response criteria is needed for childhood, adolescence, and young adulthood Hodgkin lymphoma. Two Hodgkin lymphoma protocols from cooperative trials in Europe and North America were compared for areas in need of harmonization, and an evidence-based approach is currently underway to harmonize staging and response evaluations with a goal to enhance comparisons, expedite identification of effective therapies, and aid in the approval process for new agents by regulatory agencies.
Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article.
| Filename | Description |
|---|---|
| pbc26421-sup-0001-TableS1.docx18.7 KB | SUPPLEMENTARY TABLE S1 Published response definitions for adult lymphomas. |
| pbc26421-sup-0002-FigureS2.pdf11.2 KB | SUPPLEMENTARY FIGURE S2 Criteria for grading the levels of evidence and strength of recommendation. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Mauz-Korholz C, Hasenclever D, Dorffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010; 28: 3680–3686.
- 2Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009; 114: 2051–2059.
- 3Mauz-Korholz C, Metzger ML, Kelly KM, et al. Pediatric Hodgkin lymphoma. J Clin Oncol. 2015; 33: 2975–2985.
- 4Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989; 7: 1630–1636.
- 5Connors JM, Klimo P. Is it an E lesion or stage IV? An unsettled issue in Hodgkin's disease staging. J Clin Oncol. 1984; 2: 1421–1423.
- 6Pfistner B, Diehl V, Greb A, et al. International harmonization of trial parameters in malignant lymphoma. Eur J Haematol Suppl. 2005 Jul;( 66): 53–54.
10.1111/j.1600-0609.2005.00455.x Google Scholar
- 71st International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma, Arlington, VA, USA, May 12–14, 2011: IISCAYAHL Abstracts. Pediatric Blood Cancer. 2011; 56(5): 876–894.
10.1002/pbc.23064 Google Scholar
- 8 Second International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma, in (ed Issue 2 Volume 226), Klinische Pädiatrie, 2014.
- 9Appel BE, Chen L, Buxton AB, et al. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group. J Clin Oncol. 2016; 34: 2372–2379.
- 10Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014; 32: 3651–3658.
- 11Purz S, Mauz-Korholz C, Korholz D, et al. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol. 2011; 29: 3523–3528.
- 12Cho SY, McCarten KM, Chen L, et al. 18F-FDG (FDG) PET five-point visual and quantitative SUV-based assessment and prognosis in pediatric Hodgkin lymphoma (HL). A Preliminary Retrospective Analysis of Children's Oncology Group (COG). Blood. 2012; 120; AHOD0031.
- 13Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579–586.
- 14Metzger ML, Weinstein HJ, Hudson MM, et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012; 307: 2609–2616.
- 15Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32: 3059–3068.
- 16Meignan M, Barrington S, Itti E, et al. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma. 2014; 55(1): 31–37.
- 17Kluge R, Chavdarova L, Hoffmann M, et al. Inter-reader reliability of early FDG-PET/CT response assessment using the Deauville scale after 2 cycles of intensive chemotherapy (OEPA) in Hodgkin's lymphoma. PLoS ONE. 2016; 11: e0149072.
- 18Hasenclever D, Kurch L, Mauz-Korholz C, et al. qPET—a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014; 41: 1301–1308.
- 19 Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academy of Sciences; 2011.
- 20Kremer LC, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer. 2013; 60: 543–549.
